Associations of Diagnosed Herpesvirus Infections and Antiviral Use With Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Systemic Lupus Erythematosus: A Nationwide Danish Cohort Study
Immunity, Inflammation and Disease · 2026-11 · 14 (11)
DOI: 10.1002/iid3.70609 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 19.11.2026. Verfasst von Susana Aznar und 3 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Diagnosed herpesvirus infections have been associated with several neurological and autoimmune diseases. We examined associations of recorded herpesvirus diagnoses, antiviral use, and HIV status with subsequent risk of multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and systemic lupus erythematosus (SLE).
Methods
We conducted a nationwide Danish registry‐based cohort study (1995–2018) including 48,897 individuals with a recorded HSV‐1/2, Epstein‐Barr virus (EBV), cytomegalovirus (CMV), or varicella‐zoster virus (VZV) diagnosis and 546,890 matched comparators. In a separate analysis, 5737 individuals with HIV were compared with 58,160 matched comparators. Diagnoses of MS, ALS, or SLE ≥ 5 years after infection were primary outcomes. We estimated 20‐year cumulative incidence and fitted absolute risk regression models in a competing‐risk framework.
Results
The 20‐year cumulative incidence of the composite outcome (MS, ALS, or SLE) was 0.66% among individuals with a recorded herpesvirus diagnosis and 0.38% among comparators ( p < 0.001). Disease‐specific cumulative incidence was higher for MS (0.50% vs. 0.24%, p < 0.001), similar for ALS (0.08% vs. 0.07%, p = 0.37), and slightly higher for SLE in the unadjusted analysis (0.097% vs. 0.07%, p = 0.04). After adjustment for antiviral‐use category, the model estimate for MS was 1.35 (95% CI 1.03–1.78, p = 0.03), whereas estimates for ALS and SLE were not significant. Composite‐outcome incidence was higher for recorded HSV‐1/2 and EBV diagnoses, but not CMV. In the HIV analysis, the composite outcome occurred in 3/5737 individuals with HIV and 119/58,160 comparators ( p = 0.01).
Conclusion
This nationwide study supports an epidemiological association between a recorded diagnosis and later MS risk, whereas no adjusted association was observed for ALS or SLE.
Zitieren
APA
Aznar, S., Winther‐Jensen, M., Villumsen, M., & Brudek, T. (2026). Associations of Diagnosed Herpesvirus Infections and Antiviral Use With Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Systemic Lupus Erythematosus: A Nationwide Danish Cohort Study. Immunity, Inflammation and Disease, 14(11). https://doi.org/10.1002/iid3.70609
Vancouver
Aznar S, Winther‐Jensen M, Villumsen M, Brudek T. Associations of Diagnosed Herpesvirus Infections and Antiviral Use With Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Systemic Lupus Erythematosus: A Nationwide Danish Cohort Study. Immunity, Inflammation and Disease. 2026;14(11). doi:10.1002/iid3.70609
BibTeX
@article{Aznar2026,
author = {Aznar, Susana and Winther‐Jensen, Matilde and Villumsen, Marie and Brudek, Tomasz},
title = {Associations of Diagnosed Herpesvirus Infections and Antiviral Use With Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Systemic Lupus Erythematosus: A Nationwide Danish Cohort Study},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {11},
doi = {10.1002/iid3.70609}
}
EUVIMED